SV

Syntone Ventures

North America, North Carolina, United States, Cary

Description

Syntone Ventures is a venture firm and a wholly-owned U.S.-based subsidiary of Syntone Technologies Group.

Investor Profile

Syntone Ventures has made 3 investments, with 1 in the past 12 months and 67% as lead.

Stage Focus

  • Post Ipo Equity (100%)

Country Focus

  • United States (100%)

Industry Focus

  • Biopharma
  • Biotechnology
  • Pharmaceutical
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Syntone Ventures frequently co-invest with?

Altium Capital
North America, New York, United States, New York
Co-Investments: 1
GH
Asia, Amman, Jordan, Amman
Co-Investments: 1
CP
North America, New York, United States, New York
Co-Investments: 1
Woodline Partners
North America, California, United States, San Francisco
Co-Investments: 1
Sphera Global Healthcare Fund
Asia, Tel Aviv, Israel, Tel Aviv
Co-Investments: 1
Great Point Partners
North America, Connecticut, United States, Greenwich
Co-Investments: 1
VC
North America, Georgia, United States, Alpharetta
Co-Investments: 1
Schonfeld Strategic Advisors
North America, New York, United States, New York
Co-Investments: 1
Armistice Capital
North America, New York, United States, New York
Co-Investments: 1

What are some of recent deals done by Syntone Ventures?

Outlook Therapeutics

Iselin, New Jersey, United States

Outlook Therapeutics is a biopharmaceutical company that develops ophthalmic formulations.

BiopharmaBiotechnologyPharmaceuticalTherapeutics
Post Ipo EquityApr 15, 2024
Amount Raised: $5,000,000
Outlook Therapeutics

Iselin, New Jersey, United States

Outlook Therapeutics is a biopharmaceutical company that develops ophthalmic formulations.

BiopharmaBiotechnologyPharmaceuticalTherapeutics
Post Ipo EquityJan 23, 2024
Amount Raised: $65,000,000
Outlook Therapeutics

Iselin, New Jersey, United States

Outlook Therapeutics is a biopharmaceutical company that develops ophthalmic formulations.

BiopharmaBiotechnologyPharmaceuticalTherapeutics
Post Ipo EquityMay 26, 2020
Amount Raised: $27,200,000